Vertex Pharmaceuticals (VRTX) EBT Margin (2009 - 2026)

Vertex Pharmaceuticals' EBT Margin history runs 18 years deep, the most recent figure standing at 41.95% for Q1 2026.

• On a quarterly basis, EBT Margin rose 1558.0% year-over-year to 41.95% in Q1 2026; TTM through Mar 2026 was 42.28%, a 4498.0% increase from a year earlier, with the FY2025 full-year figure at 38.69%, up 3643.0% from the prior year.
• EBT Margin improved to 41.95% in Q1 2026 per VRTX's latest filing, from 41.72% in the prior quarter.
• Across five years, EBT Margin topped out at 50.4% in Q3 2022 and bottomed at 128.18% in Q2 2024.
• The 5-year median for EBT Margin is 44.16% (2024), against an average of 33.21%.
• Across the five-year window, EBT Margin plunged 17477 bps in 2024 and jumped 17146 bps in 2025, its largest moves.
• Year by year, EBT Margin stood at 46.76% in 2022, then retreated by 3 bps to 45.58% in 2023, then declined by 14 bps to 39.03% in 2024, then grew by 7 bps to 41.72% in 2025, then advanced by 1 bps to 41.95% in 2026.
• Per Business Quant, the three latest VRTX EBT Margin figures stand at 41.95% (Q1 2026), 41.72% (Q4 2025), and 42.22% (Q3 2025).